SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.
Age ≥18;
Metastatic esophageal squamous cell carcinoma (stage IVB, M1) confirmed by pathology;
ECOG performance status: 0-1 point;
No prior anti-tumor treatment;
Non-squamous cell esophageal carcinoma or ESCC mixed with other pathological types of esophageal cancer;
Patients who are potentially curable with surgery as assessed by investigators;
Pleural metastasis or malignant pleural effusion, pericardial effusion;
Any prior anti-tumor therapy for esophageal cancer, i.e., surgery, radiotherapy, chemotherapy, or immunotherapy;